Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522742 · ClinicalTrials.gov registry record
Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 29
- Enrollment target
NCT01522742: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT01522742 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522742 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to psoriasis patients with or without arthritis by their treating clinicians) will decrease cardiovascular inflammation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522742
The ClinicalTrials.gov registry entry for NCT01522742 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01522742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522742 about?
NCT01522742 is a clinical study titled "Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study". The main aims of this study are to determine whether: a) psoriasis patients with or without arthritis have more cardiovascular inflammation than healthy subjects and b)3 months of etanercept (enbrel) therapy (prescribed to psoriasis patients with or without arthritis by their treating clinicians) wi...
What is the current status of trial NCT01522742?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2012-02. Estimated completion is 2016-01.
Who is sponsoring clinical trial NCT01522742?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.